ABCDEFGHIJKLMNOPQRSTUV
1
status as of October 2022developermanufacturermanufacturer countryvaccineplatformannouncement urldate tech transfer deal was announcedquarter announcedtime between agreement annoucement date and estimated or actual manufacture start date_1time between agreement annoucement date and estimated or actual manufacture start date_2time between agreement annoucement date and estimated or actual manufacture start date_3details about the estimated or actual manufacturing start dateonly involves fill-and-finish or other substances aside from active ingredientsdetails about the manufacturing steps or activities to be carried outstage of development when tech transfer deal was announcedmonths between the phase 3 trial and the tech transfer deal datedate when earliest phase 3 trial startedmonths between approval and the tech transfer deal datedate of first known authorizationplace of first known authorizationdate
2
authorizedPfizer/BioNTechPolymunAustriaBNT162b2mRNAhttps://investors.biontech.de/news-releases/news-release-details/biontech-reports-rapid-progress-covid-19-vaccine-program-address/March 16, 20202020 Q1phase 1-4.4July 27, 2020-8.6December 2, 2020United Kingdom2020-3
3
phase 3InovioOlogy BioservicesUnited StatesINO-4800DNA-basedhttps://www.prnewswire.com/news-releases/ology-bioservices-inovio-partner-to-manufacture-covid-19-dna-vaccine-with-11-9-million-department-of-defense-grant-301028626.htmlMarch 24, 20202020 Q1---entire process, active ingredient, others"Ology Bioservices will work with Inovio Pharmaceuticals to manufacture Inovio's DNA vaccine (INO-4800) for prevention of infection with the COVID-19 virus"pre-clinical-8.0November 24, 20202020-3
4
authorizedJohnson & JohnsonEmergent BioSolutionsUnited StatesAd26.COV2-Sviral vectorhttps://www.jnj.com/johnson-johnson-announces-collaboration-to-expand-manufacturing-capabilities-for-its-covid-19-vaccine-candidate-in-support-of-the-companys-goal-to-supply-more-than-one-billion-vaccine-doses-globallyApril 23, 20202020 Q2nine months9-127-9according to Emergent, when the announcement was made delivery was set to start at the begining of 2021. However, it is likely that they held of from starting delivery earlier to wait for the regulatory authorization of the vaccine, which was still several months away when the tech transfer deal was signed: https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-five-year-agreement-large-scale-drug entire process, active ingredient, others"Emergent will provide drug substance manufacturing services with its molecule-to-market CDMO offering, beginning in 2020, and will also reserve operations capacity to potentially support commercial manufacturing of Johnson & Johnson’s COVID-19 vaccine candidate leveraging Janssen’s proven AdVac® and PER.C6® technologies beginning in 2021"pre-clinical-3.6August 10, 2020-10.2February 27, 2021United States2020-4
5
authorizedJohnson & JohnsonCatalentUnited StatesAd26.COV2-Sviral vectorhttps://www.catalent.com/catalent-news/catalent-signs-agreement-with-johnson-johnson-for-lead-covid-19-vaccine-candidate/April 29, 20202020 Q2eight months7-87-9"Catalent plans to hire approximately 300 additional employees at the site for this program starting in July 2020 to meet operational readiness and 24×7 manufacturing schedules by January 2021."entire process, active ingredient, others"Catalent’s Biologics business unit will accelerate availability of manufacturing capacity and prepare for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnson’s lead vaccine candidate for COVID-19"pre-clinical-3.4August 10, 2020-10.0February 27, 2021United States2020-4
6
phase 3InovioRichter-Helm BioLogics GmbH & CoGermanyINO-4800DNA-basedhttps://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Expands-Manufacturing-of-COVID-19-DNA-Vaccine-INO-4800-With-New-Funding-from-CEPI/default.aspxApril 30, 20202020 Q2---entire process, active ingredient, others"large-scale manufacturing of INOVIO's investigational DNA vaccine INO-4800"phase 1-6.8November 24, 20202020-4
7
authorizedModernaLonzaSwitzerlandmRNA-1273mRNAhttps://www7.lonza.com/~/media/Files/japan/News/200501_Press_Release__Moderna_Lonza_COVID_FINAL.pdfMay 1, 20202020 Q2one month1-21-3"Technology transfer is expected to begin in June 2020, and the companies intend to manufacture the first batches of mRNA-1273 at Lonza U.S. in July 2020"entire process, active ingredient, others"Under the terms of the agreement, the companiesplan toestablish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.Technology transfer is expected to begin in June2020, and the companies intend to manufacture the first batches of mRNA-1273 at Lonza U.S. in July 2020."phase 1-2.9July 27, 2020-7.6December 18, 2020United States2020-5
8
phase 2Arcturus TherapeuticsCatalentUnited StatesARCT-021, LUNAR-COV19RNA-basedhttps://www.catalent.com/catalent-news/arcturus-therapeutics-and-catalent-announce-partnership-to-manufacture-mrna-based-covid-19-vaccine/May 4, 20202020 Q2two months1-21-3"Technology transfer will be completed this month and manufacture of the first cGMP batches of LUNAR-COV19 mRNA are expected to be completed by June 2020." https://www.catalent.com/catalent-news/arcturus-therapeutics-and-catalent-announce-partnership-to-manufacture-mrna-based-covid-19-vaccine/ entire process, active ingredient, others"The manufacture of LUNAR-COV19 at Catalent’s state-of-the-art drug substance biomanufacturing facility in Madison, Wisconsin will support human clinical studies and, if successful, commercialization of the vaccine. The COVID-19 vaccine program will take advantage of the facility’s flex-suite, a cGMP manufacturing suite that can produce batches at multiple scales and support Arcturus’ proprietary mRNA manufacturing process."pre-clinical2020-5
9
authorizedJohnson & JohnsonVibalogicsGermanyAd26.COV2-Sviral vectorhttps://vibalogics.com/vibalogics-announces-collaboration-with-janssens-to-provide-additional-clinical-trial-material-for-covid-19-vaccine-candidate/May 14, 20202020 Q2---entire process, active ingredient, others"From its GMP accredited facility in Cuxhaven, Germany, the company is contracted to manufacture multiple batches, which will result in many thousands of doses of an investigational COVID-19 vaccine candidate."pre-clinical-2.9August 10, 2020-9.5February 27, 2021United States2020-5
10
authorizedModernaCordenPharmaFrancemRNA-1273mRNAhttps://www.cordenpharma.com/CordenPharma_and_Moderna_Extend_Lipid_Supply_Agreement_for_Moderna_Vaccine_mRNA-1273_Against_Novel_Coronavirus_SARS-CoV-2May 28, 20202020 Q2---lipid supply agreemententire process, active ingredient, others"manufacture large-scale volumes of Moderna’s lipid excipients to be used in the manufacture of Moderna’s vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2)."phase 2-2.0July 27, 2020-6.7December 18, 2020United States2020-5
11
authorizedAstraZeneca/OxfordOxford BiomedicaUnited KingdomAZD1222viral vectorhttps://www.oxb.com/news-media/press-release/oxford-biomedica-signs-clinical-commercial-supply-agreement-astrazenecaMay 28, 20202020 Q2four months3-44-6According to a September 17, 2020 interview, Oxford Biomedica was already producing: https://www.youtube.com/watch?v=fc4eK09tnIU entire process, active ingredient, others"AstraZeneca will have access to Oxford Biomedica’s new 7,800 m2 commercial manufacturing centre Oxbox, located in Oxford, UK. In April 2020 Oxford Biomedica announced that it had joined a consortium including the Jenner Institute in relation to the potential for large scale manufacture of AZD1222"phase 2/30.1May 26, 2020-7.1December 30, 2020United Kingdom, Argentina2020-5
12
authorizedNovavaxAGC BiologicsDenmarkNVX-CoV2373protein-basedhttp://www.agcbio.com/news/novavax-selects-agc-biologics-to-manufacture-matrix-m-adjuvant-for-novel-covid-19-vaccineJune 3, 20202020 Q2eight months7-87-9Novavax said that this agreement could help them deliver doses "in 2020": https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000110465920092782/nvax-20200630x10q.htmentire process, active ingredient, others"AGC Biologics will manufacture Matrix-M™, the adjuvant component of the vaccine, in order to enhance the immune response and stimulate high levels of neutralizing antibodies."phase 1/2-4.3October 12, 2020-18.6December 20, 2021EMA2020-6
13
authorizedAstraZeneca/OxfordSerum InstituteIndiaAZD1222viral vectorhttps://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-takes-next-steps-towards-broad-and-equitable-access-to-oxford-universitys-potential-covid-19-vaccine.htmlJune 4, 20202020 Q2six months5-64-6On November 12, 2020. SII said it had already produced 40 million doses of the AZ vaccineentire process, active ingredient, others"supply one billion doses for low-and-middle-income countries, with a commitment to provide 400 million before the end of 2020."phase 2/30.3May 26, 2020-6.9December 30, 2020United Kingdom, Argentina2020-6
14
authorizedNovavaxPolyPeptide GroupSwitzerlandNVX-CoV2373protein-basedhttps://www.polypeptide.com/press-release-polypeptide-group-selected-by-novavax-to-manufacture-critical-intermediates-of-matrix-m-adjuvant-for-its-covid-19-vaccine/June 4, 20202020 Q2---"In June 2020, we entered into contract manufacturing arrangements with AGC Biologics and the Polypeptide Group to provide contract development and manufacturing services, supplying us with large-scale production of Matrix-M. These arrangements are expected to allow us to significantly increase our capacity to deliver doses of NVX-CoV2373 in 2020 and 2021." https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000110465920092782/nvax-20200630x10q.htmentire process, active ingredient, others"PolyPeptide Group will produce two key intermediates used in the production of Matrix-M™, the adjuvant component of the vaccine, which is being used to enhance the vaccine’s immune response and stimulate high levels of neutralizing antibodies."phase 1/2-4.3October 12, 2020-18.5December 20, 2021EMA2020-6
15
authorizedSinovacButantan InstituteBrazilCoronaVacinactivated virushttps://www.biospace.com/article/releases/sinovac-and-butantan-join-efforts-to-advance-the-clinical-development-of-an-inactivated-vaccine-for-covid-19-to-phase-iii/June 11, 20202020 Q2six months5-64-6"The Butantan Institute, a Brazilian biological research center, has started manufacturing CoronaVac, a vaccine against the novel coronavirus (COVID-19), still in its testing phase. Production will be conducted in partnership with Chinese pharmaceutical company Sinovac." https://agenciabrasil.ebc.com.br/en/saude/noticia/2020-12/brazilian-institute-start-production-vaccine-coronavacfill-and-finishfill-and-finishphase 1/2-0.7July 2, 2020-7.0January 11, 2021Indonesia2020-6
16
authorizedAstraZeneca/OxfordEmergent BioSolutionsUnited StatesAZD1222viral vectorhttps://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing-0?field_nir_news_date_value%5Bmin%5D=June 11, 20202020 Q2seven months7-87-9Manufacturing started as of February 2021, per Emergent BioSolutions CEO Bob Kramer interviewentire process, active ingredient, others"Emergent will provide development services, technology transfer, analytical testing, drug substance process and performance qualification and will reserve certain large-scale manufacturing capacity through 2020."phase 2/30.5May 26, 2020-6.6December 30, 2020United Kingdom, Argentina2020-6
17
authorizedAstraZeneca/OxfordNovasep (plant acquired by Thermo Fisher)FranceAZD1222viral vectorhttps://web.archive.org/web/20201127123206/https://www.novasep.com/home/about-novasep/media-events/press-release/coronavirus-novasep-partners-with-astrazeneca-to-produce-covid-19-oxford-vaccine-for-europe.htmlJune 15, 20202020 Q2seven months7-87-9althought with shortfalls, Novasep was already producing by January 2021 according to reports: https://www.wsj.com/articles/astrazenecas-covid-19-vaccine-shortfall-threatens-eu-plans-to-boost-inoculations-11611423256entire process, active ingredient, otherslarge-scale production of adenovirus vectorsphase 2/30.7May 26, 2020-6.5December 30, 2020United Kingdom, Argentina2020-6
18
authorizedAstraZeneca/OxfordCatalentUnited StatesAZD1222viral vectorhttps://www.catalent.com/catalent-news/catalent-signs-agreement-with-astrazeneca-to-manufacture-covid-19-vaccine-candidate/June 15, 20202020 Q2three months3-41-3"Catalent will prepare the facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of the vaccine candidate from August 2020, and potentially through to March 2022 should the product be approved by regulatory agencies."entire process, active ingredient, others"Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca PLC at Catalent’s manufacturing facility in Anagni, Italy, and prepare for large-scale commercial supply of the University of Oxford’s adenovirus vector based COVID-19 vaccine candidate, AZD1222." phase 2/30.7May 26, 2020-6.5December 30, 2020United Kingdom, Argentina2020-6
19
authorizedAstraZeneca/OxfordCobra BiologicsUnited StatesAZD1222viral vectorhttps://www.cobrabio.com/news/june-2020/cobra-supply-agreement-astrazeneca-covid19-vaccineJune 16, 20202020 Q2three months3-41-3September 2020entire process, active ingredient, others"GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19."phase 2/30.7May 26, 2020-6.5December 30, 2020United Kingdom, Argentina2020-6
20
authorizedModernaCatalentUnited StatesmRNA-1273mRNAhttps://www.catalent.com/catalent-news/moderna-and-catalent-announce-collaboration-for-fill-finish-manufacturing-of-modernas-covid-19-vaccine-candidate/June 25, 20202020 Q2three months3-41-3"third quarter of 2020"fill-and-finishfill-and-finishphase 2-1.1July 27, 2020-5.8December 18, 2020United States2020-6
21
authorizedAstraZeneca/OxfordFiocruzBrazilAZD1222viral vectorhttps://portal.fiocruz.br/en/news/covid-19-fiocruz-will-sign-agreement-produce-vaccines-university-oxford#:~:text=The%20Oswaldo%20Cruz%20Foundation%20(Fiocruz,by%20the%20University%20of%20Oxford.&text=Combined%20with%20other%20actions%2C%20it,fight%20the%20Covid%2D19%20pandemic.June 30, 20202020 Q2six months5-64-6December 2020entire process, active ingredient, others"The investment includes not only the vaccine batches, but also the transference of technology, so that the production can be fully internalized and national."phase 2/31.1May 26, 2020-6.0December 30, 2020United Kingdom, Argentina2020-6
22
authorizedMedicagoGlaxoSmithKlineUnited KingdomCovifenzvirus-like particleshttps://www.medicago.com/en/media-room/gsk-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-candidate-vaccine/July 7, 20202020 Q3---entire process, active ingredient, others"The companies will use Medicago's plant-based production platform to manufacture the COVID-19 vaccine antigen. This innovative technology uses the leaves of a plant as bioreactors to produce the S-spike protein which self-assemble into VLPs for use in the CoVLP vaccine candidate. It is highly scalable and can support the production of large amounts of vaccine in a significantly shortened timeline."pre-clinical-4.4November 19, 2020-19.6February 24, 2022Canada2020-7
23
authorizedModernaROVISpainmRNA-1273mRNAhttps://investors.modernatx.com/news-releases/news-release-details/moderna-and-rovi-announce-collaboration-ous-fill-finishJuly 9, 20202020 Q3eight months7-87-9"starting in early 2021"fill-and-finish"ROVI will provide vial filling and packaging capacity by procuring a new production line and equipment for compounding, filling, automatic visual inspection and labeling to support production of hundreds of millions of doses of the vaccine candidate intended in principle to supply markets outside of the U.S. starting in early 2021."phase 2-0.6July 27, 2020-5.3December 18, 2020United States2020-7
24
authorizedAstraZeneca/OxfordR-PharmRussian FederationAZD1222viral vectorhttps://www.reuters.com/article/us-health-coronavirus-cyber-russia-vacci/russias-r-pharm-signs-deal-to-make-uk-developed-covid-19-vaccine-idUSKCN24I1XFJuly 17, 20202020 Q3twelve months9-1210-12R-Pharm said in May 2021 that they were starting exports in June 2021: https://gxpnews.net/en/2021/05/r-pharm-plans-to-release-a-batch-of-astrazeneca-vaccine-in-june/entire process, active ingredient, others"manufacture a COVID-19 vaccine being developed by the British pharmaceuticals giant and Oxford University, it said on Friday."phase 2/31.7May 26, 2020-5.5December 30, 2020United Kingdom, Argentina2020-7
25
authorizedAstraZeneca/OxfordSK BioscienceSouth KoreaAZD1222viral vectorhttps://www.reuters.com/article/us-health-coronavirus-southkorea-astraze/south-koreas-sk-bioscience-in-deal-with-astrazeneca-on-vaccine-idUSKCN24M0ZFJuly 21, 20202020 Q3four months3-44-6According to news reports, SK Bioscience was already producting by late November 2020: http://www.koreaherald.com/view.php?ud=20201120000748 entire process, active ingredient, others"SK Bioscience, a unit of SK Chemicals, said it will start producing undiluted solutions of the vaccine after discussing production plans with AstraZeneca."phase 2/31.8May 26, 2020-5.3December 30, 2020United Kingdom, Argentina2020-7
26
authorizedNovavaxFUJIFILM Diosynth BiotechnologiesJapanNVX-CoV2373protein-basedhttps://fujifilmdiosynth.com/about-us/news/novavax-and-fujifilm-diosynth-biotechnologies-initiate-large-scale-manufacturing-of-covid-19-vaccine-candidate/July 23, 20202020 Q3six months5-64-6Two facilities were already producing by January 2021: https://www.fujifilm.com/us/en/news/FUJIFILM-Diosynth-Biotechnologies-Begins-Manufacture-of-COVID-19-Vaccine-in-Texasentire process, active ingredient, others"manufacture bulk drug substance for NVX-CoV2373"phase 1/2-2.7October 12, 2020-16.9December 20, 2021EMA2020-7
27
n/aIntravaccCelonic GroupSwitzerlandCovOMVprotein-basedhttps://www.celonic.com/general/intravacc-and-celonic-to-develop-and-produce-a-novel-covid-19-vaccine/July 29, 20202020 Q3---entire process, active ingredient, others"Swiss based Celonic Group will construct cell lines producing the S-protein in high quantities and develop a GMP production process."pre-clinical2020-7
28
authorizedAstraZeneca/OxfordWockhardt, CP PharmaceuticalsUnited KingdomAZD1222viral vectorhttp://www.wockhardt.com/pdfs/press-release-wockhardt-03-08-20.pdfAugust 2, 20202020 Q3six months5-64-6Wockhardt said in December 2020 that they were prepare to manufacture 100 million doses, pending regulatory approval: https://scrip.pharmaintelligence.informa.com/SC143408/Wockhardt-Preps-To-Deliver-100M-Doses-Of-AZ-Vaccinefill-and-finish"Wockhardt, the global pharmaceutical and biotechnology major today announced that it has entered into an agreement with the UK Government to fill finish COVID-19 vaccines." phase 2/32.2May 26, 2020-4.9December 30, 2020United Kingdom, Argentina2020-8
29
authorizedGamaleyaGeneriumRussiaSputnik Vviral vectorhttps://tass.com/society/1185199August 3, 20202020 Q3three months1-21-3Production launched in October: https://www.generium.ru/en/news/generium-launched-the-production-of-sputnik-v-vaccine/-0.8August 28, 2020-4.6December 21, 2020Belarus2020-8
30
phase 3AnGesKaneka EurogentecBelgiumAG0302-COVID19DNA-basedhttps://www.kaneka.co.jp/en/topics/news/2020/ennr2008041.htmlAugust 4, 20202020 Q3---entire process, active ingredient, others"Kaneka Eurogentec, an affiliate of Kaneka Corporation, will join the task force led by Takara Bio Inc. that will aim to mass produce a DNA vaccine for the novel coronavirus, which is being developed by AnGes Inc."phase 1/2-3.6November 23, 2020pending authorizationpending authorization2020-8
31
authorizedAstraZeneca/OxfordBioKangtaiChinaAZD1222viral vectorhttps://www.fiercepharma.com/manufacturing/astrazeneca-takes-covid-19-vaccine-to-china-biokangtai-deal-for-200m-dose-capacity-byAugust 6, 20202020 Q3six months5-64-6https://www.reuters.com/article/us-health-coronavirus-kangtai-astrazenec/astrazenecas-china-partner-expects-to-be-able-to-make-400-million-covid-19-vaccine-doses-a-year-idUSKBN2A20VB2.4May 26, 2020-4.8December 30, 2020United Kingdom, Argentina2020-8
32
authorizedAstraZeneca/OxfordShenzhen Kangtai Biological ProductsChinaAZD1222viral vectorhttps://www.biospace.com/article/astrazeneca-inks-covid-19-vaccine-deal-with-china-s-shenzhen-kangtai/August 6, 20202020 Q3six months5-64-6Shenzhen Kangtai said on February 1, 2021, that it had completed building a new facility and started production: https://www.reuters.com/article/health-coronavirus-kangtai-astrazeneca-idCNL1N2K80GN When the deal was announced in August 2020 news reports said that the company had to delivery 100 million doses by December 2020: https://www.bioworld.com/articles/496620-astrazeneca-partners-with-kangtai-bio-to-bring-covid-19-vaccine-to-chinaentire process, active ingredient, others"manufacture AstraZeneca and the University of Oxford’s COVID-19 vaccine in mainland China"phase 2/32.4May 26, 2020-4.8December 30, 2020United Kingdom, Argentina2020-8
33
authorizedNovavaxSerum InstituteIndiaNVX-CoV2373protein-basedhttps://ir.novavax.com/news-releases/news-release-details/novavax-and-serum-institute-india-announce-development-andAugust 6, 20202020 Q3----entire process, active ingredient, others"For LMICs and India, Novavax and SIIPL are partnering on clinical development, co-formulation, filling and finishing and commercialization of NVX-CoV2373. SIIPL will be responsible for regulatory submissions and marketing authorizations. Novavax will provide to SIIPL both vaccine antigen and Matrix‑M adjuvant, and Novavax and SIIPL are in discussions to have SIIPL manufacture vaccine antigen in India. Novavax and SIIPL will split the revenue from the sale of product, net of agreed costs." phase 1/2-2.2October 12, 2020-16.5December 20, 2021EMA2020-8
34
authorizedAstraZeneca/OxfordVaccines Manufacturing and Innovation Centre (VMIC)United KingdomAZD1222viral vectorhttps://web.archive.org/web/20201024125213/https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-signs-five-year-collaboration-agreement-vaccinesAugust 6, 20202020 Q3----entire process, active ingredient, others"VMIC will provide manufacturing equipment for Oxford Biomedica to rapidly equip two new GMP manufacturing suites within Oxford Biomedica’s new 7,800 m2 commercial manufacturing centre, Oxbox, located in Oxford, UK"phase 2/32.4May 26, 2020-4.8December 30, 2020United Kingdom, Argentina2020-8
35
authorizedGamaleyaTecparBrazilSputnik Vviral vectorhttps://rdif.ru/Eng_fullNews/5574/August 12, 20202020 Q3---entire process, active ingredient, others"RDIF together with pharmaceutical companies in the state of Parana will organize the production of the “Sputnik V” vaccine and its distribution in Brazil and other Latin American countries."phase 2-0.5August 28, 2020-4.3December 21, 2020Belarus2020-8
36
authorizedJohnson & JohnsonBiological EIndiaAd26.COV2-Sviral vectorhttps://www.biologicale.com/news.htmlAugust 13, 20202020 Q3---entire process, active ingredient, others"for the creation / enhancement of manufacturing capacities for drug substance and drug product for Johnson & Johnson’s COVID-19 vaccine candidate, Ad26.COV2.S. Johnson & Johnson’s COVID-19 vaccine candidate is currently in Phase 1/2a clinical trials."phase 1/20.1August 10, 2020-6.5February 27, 2021United States2020-8
37
authorizedBaylorBiological EIndiaCorbevaxprotein-basedhttps://www.bcm.edu/news/baylor-and-biological-e-limited-team-up-for-a-global-covid-19-vaccineAugust 13, 20202020 Q3entire process, active ingredient, otherspre-clinical-10.7July 6, 2021-16.5December 28, 2021India2020-8
38
authorizedNovavaxSK BioscienceSouth KoreaNVX-CoV2373protein-basedhttps://ir.novavax.com/news-releases/news-release-details/novavax-and-sk-bioscience-announce-collaboration-novavax-covidAugust 13, 20202020 Q3one month1-21-3"beginning in August 2020"entire process, active ingredient, others"SK bioscience will manufacture the vaccine antigen component for use in the final drug product globally during the pandemic period"phase 1/2-2.0October 12, 2020-16.2December 20, 2021EMA2020-8
39
authorizedCanSino BiologicsPetrovaxRussiaAd5-nCoVviral vectorhttps://petrovax.com/press_centre/news/2020/1878/August 15, 20202020 Q3five months5-64-6By December 2021, Petrovax had already launch a phase 3 trial and said that it was ready to manufacture at commercial scale. https://petrovax.com/press_centre/news/2020/2085/-0.4August 26, 2020-5.9February 10, 2021Mexico2020-8
40
authorizedAstraZeneca/OxfordmAbxienceArgentinaAZD1222viral vectorhttps://www.mabxience.com/mabxience-enters-into-an-agreement-with-astrazeneca-to-produce-covid-19-vaccine/August 17, 20202020 Q3four months3-44-6Hugo Sigman announced on November 13, 2020, that production would start in two weeks. entire process, active ingredient, others"produce the active ingredient, which will subsequently be sent to Mexico to complete the production and filling process."phase 2/32.7May 26, 2020-4.4December 30, 2020United Kingdom, Argentina2020-8
41
authorizedAstraZeneca/OxfordLaboratorio LiomontMexicoAZD1222viral vectorhttps://elpais.com/mexico/sociedad/2021-05-10/mexico-distribuira-la-vacuna-latinoamericana-a-finales-de-mayo-despues-de-semanas-de-atraso.htmlAugust 17, 20202020 Q3six months5-64-6"El plan original, confirmado por Ebrard, suponía que las vacunas comenzarían a entregarse en abril"fill-and-finishphase 2/32.7May 26, 2020-4.4December 30, 2020United Kingdom, Argentina2020-8
42
authorizedSinovacBio FarmaIndonesiaCoronaVacinactivated virushttps://www.biospace.com/article/releases/sinovac-signs-agreement-with-bio-farma-indonesia-for-covid-19-vaccine-cooperation/August 25, 20202020 Q3six months5-64-6"As of Thursday, January 21, there have been 4 million doses that have been produced. The status of these products is in the process of quality control, which will be sent to the POM to get a lot release so that it can be distributed, and it is estimated that until February. In the coming 2021, 4 million doses of vaccine will be ready, "said Director of Bio Farma, Honesti Basyir in an official statement received in Jakarta, reported by Antara, Saturday, January 23." https://voi.id/en/news/28470/bio-farma-is-ready-to-distribute-4-million-doses-of-covid-19-vaccine-in-february fill-and-finishSinovac is committed to supply Bio Farma bulk vaccine to enable the latter to produce at least 40 million doses of CoronaVac in Indonesia before March 2021phase 31.8July 2, 2020-4.6January 11, 2021Indonesia2020-8
43
authorizedSinopharmBCHT BioteknologiIndonesiaBBIBP-CorVinactivated virushttps://www.cnbcindonesia.com/news/20200812184641-4-179386/jokowi-siapkan-rp-50-t-buat-vaksin-covid-19August 25, 20202020 Q3---entire process, active ingredient, others-phase 30.4August 12, 2020-3.5December 9, 2020United Arab Emirates2020-8
44
authorizedSinopharmBio FarmaIndonesiaBBIBP-CorVinactivated virushttps://asia.nikkei.com/Spotlight/Coronavirus/Indonesia-teams-with-China-s-Sinovac-for-COVID-vaccineAugust 25, 20202020 Q3---fill-and-finishfill-and-finishphase 30.4August 12, 2020-3.5December 9, 2020United Arab Emirates2020-8
45
authorizedAstraZeneca/OxfordAlbany Molecular ResearchUnited StatesAZD1222viral vectorhttps://www.amriglobal.com/blog/news-and-events/news/amri-selected-to-support-astrazeneca-in-delivery-of-covid-19-vaccine/September 3, 20202020 Q3four months3-44-6Albany Molecular Research said in January 2021 that their Albuquerque location was "currently supporting COVID-19 vaccine production." Albuquerque is the location were Albany agreed to do fill-and-finish for AZ. https://www.amriglobal.com/blog/news-and-events/news/amri-included-in-barda-cdmo-network-in-support-of-covid-19-pandemic-response-in-the-u-s/fill-and-finishfill-and-finishphase 2/33.3May 26, 2020-3.9December 30, 2020United Kingdom, Argentina2020-9
46
authorizedAstraZeneca/OxfordCSL Behring Ltd.AustraliaAZD1222viral vectorhttps://www.csl.com/news/2020/20200907-csl-to-manufacture-and-supply-uq-and-ou-vaccine-candidates-for-australiaSeptember 7, 20202020 Q3three months3-41-3CSL said that it will start manufacturing on November 9, 2020: https://www.csl.com/news/2020/20201108-csl-commences-manufacturing-of-university-of-oxford-astrazeneca-vaccine-candidate It is unclear when this deal was first announced, but it appears to be either July or August. entire process, active ingredient, others"manufacture approximately 30 million doses of the AZD1222 vaccine candidate, with first doses planned for release to Australia early next year"phase 2/33.4May 26, 2020-3.7December 30, 2020United Kingdom, Argentina2020-9
47
abandonedUniversity of QueenslandCSL Behring Ltd.AustraliaV451protein-basedhttps://www.csl.com/news/2020/20200907-csl-to-manufacture-and-supply-uq-and-ou-vaccine-candidates-for-australiaSeptember 7, 20202020 Q3eight months7-87-9"mid-2021"entire process, active ingredient, others"supply of 51 million doses"phase 1abandonedabandoned2020-9
48
phase 3InovioThermo FisherUnited StatesINO-4800DNA-basedhttp://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Adds-Thermo-Fisher-Scientific-To-Global-Manufacturing-Consortium/default.aspxSeptember 8, 20202020 Q3---entire process, active ingredient, others"manufacture INO-4800 drug substance as well as perform fill and finish of INO-4800 drug product at its commercial facilities in the US"phase 2-2.5November 24, 20202020-9
49
authorizedPfizer/BioNTechDermapharmGermanyBNT162b2mRNAhttps://www.pharmiweb.com/press-release/2020-09-10/dermapharm-holding-se-signs-cooperation-and-delivery-agreement-with-biontech-se-on-the-productionSeptember 10, 20202020 Q3three months3-41-3"Dermapharm Holding SE ("Dermapharm"), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, will support the vaccine developer BioNTech SE in part of the vaccine production of BNT162b2 starting in the fourth quarter of 2020. Once approval for the vaccine has been received, the Dermapharm Group will make production capacities available and expand them at its German site in order to offer BioNTech the greatest possible support." https://www.pharmiweb.com/press-release/2020-09-10/dermapharm-holding-se-signs-cooperation-and-delivery-agreement-with-biontech-se-on-the-production fill-and-finish"The active ingredient, the mRNA, is manufactured in Germany by BioNTech."phase 31.5July 27, 2020-2.7December 2, 2020United Kingdom2020-9
50
authorizedPfizer/BioNTechSiegfriedSwitzerlandBNT162b2mRNAhttps://www.siegfried.ch/pages/mod/getMedById.cfm?medId=14212September 14, 20202020 Q3---fill-and-finish"large-scale filling and packaging of commercial quantities of BNT162b2"phase 31.6July 27, 2020-2.6December 2, 2020United Kingdom2020-9
51
authorizedNovavaxBiofabriSpainNVX-CoV2373protein-basedhttps://ir.novavax.com/news-releases/news-release-details/novavax-announces-covid-19-vaccine-manufacturing-agreement-serumSeptember 15, 20202020 Q3six months5-64-6Biofabri CEO said in March 2021 that they were already producing 1,000 liters of the Novavax antigent per week: https://www.farodevigo.es/sociedad/2021/03/13/fabricamos-lotes-semanales-1-000-41671474.htmlentire process, active ingredient, others"antigen component of NVX-CoV2373"phase 1/2-0.9October 12, 2020-15.1December 20, 2021EMA2020-9
52
authorizedGamaleyaDr Reddy'sIndiaSputnik Vviral vectorhttps://www.drreddys.com/media/904781/sputnikv-india_dr-reddys.pdfSeptember 16, 20202020 Q3four months3-44-6"Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India." https://www.drreddys.com/media/904781/sputnikv-india_dr-reddys.pdfentire process, active ingredient, others-phase 1/20.6August 28, 2020-3.2December 21, 2020Belarus2020-9
53
authorizedGamaleyaPharco PharmaceuticalsEgyptSputnik Vviral vectorhttps://www.prnewswire.com/ae/news-releases/rdif-and-pharco-agree-to-supply-25-million-doses-of-sputnik-v-vaccine-to-egypt-823006786.htmlSeptember 20, 20202020 Q3seven months7-87-9"Local reports last year say that Pharco will start manufacturing the Russian vaccine starting April as per a memorandum of understanding between Biogenix Corporation, an affiliate of Pharco Pharmaceutical Group, and the RIF." https://english.ahram.org.eg/NewsContent/1/64/404860/Egypt/Politics-/Egypts-coronavirus-vaccination-campaign-A-timeline.aspxfill-and-finishfill-and-finishphase 1/20.8August 28, 2020-3.0December 21, 2020Belarus2020-9
54
authorizedCanSino BiologicsSolbioMalaysiaAd5-nCoVviral vectorhttps://www.businesstoday.com.my/2020/09/29/solbio-forges-partnership-with-cansino-biologics-to-distribute-coronavirus-vaccine-in-malaysia/September 23, 20202020 Q3six months5-64-6Malaysia started receiving filled and finished vaccines in April 2021. "He said the procurement of the vaccine is being made in two categories, namely finished product of 500,000 doses, and the rest delivery in bulk to be filled and packaged by local company Solutions Biologics Sdn Bhd (SolBio)." https://www.thestar.com.my/news/nation/2021/04/01/malaysia-will-start-receiving-cansino-covid-19-vaccine-from-this-month fill-and-finish"SOLBIO will establish a “state-of-the-art” fill and finish facility while CanSinoBio will provide the technology transfer and relevant technical know-how for the operation of the facility."phase 30.9August 26, 2020-4.6February 10, 2021Mexico2020-9
55
authorizedGamaleyaBIOCADRussiaSputnik Vviral vectorhttps://sputniknews.com/20200924/russian-biotech-company-biocad-set-to-produce-covid-19-vaccine-sputnik-v-1080556918.htmlSeptember 24, 20202020 Q3four months3-44-6Althought with challenges, they were scaling up by December 2020. https://www.wsj.com/articles/russia-struggles-to-make-promised-doses-of-its-sputnik-v-vaccine-11607601609 and producing by April 2021: https://tass.com/society/12735330.9August 28, 2020-2.9December 21, 2020Belarus2020-9
56
authorizedNovavaxEndo InternationalUnited StatesNVX-CoV2373protein-basedhttps://investor.endo.com/news-releases/news-release-details/endo-announces-fill-finish-manufacturing-and-services-agreementSeptember 25, 20202020 Q3one month1-21-3"Under the terms of the agreement, Par Sterile's Rochester facility has begun production of NVX-CoV2373 final drug product, with initial batches to be used in Novavax' pivotal Phase 3 clinical trial in the United States."fill-and-finishfill and finishphase 3-0.6October 12, 2020-14.8December 20, 2021EMA2020-9
57
authorizedJohnson & JohnsonGrand River Aseptic Manufacturing (GRAM)United StatesAd26.COV2-Sviral vectorhttps://www.grandriverasepticmfg.com/news/gram-partners-with-johnson-johnson-on-manufacturing-in-fight-against-covid-19/September 25, 20202020 Q3three months3-41-3When the J&J vaccine was authorized there were news reports suggesting that GRAM had been manufacturing since the Fall 2020: https://www.youtube.com/watch?v=A8zLMxwPJNg In late February 2020 GRAM said that they had been manufacturing "for a few months": https://www.youtube.com/watch?v=L5CFaowp0Qofill-and-finish"technical transfer and fill and finish manufacture"phase 31.5August 10, 2020-5.1February 27, 2021United States2020-9
58
authorizedGamaleyaBelmedpreparatyBelarusSputnik Vviral vectorhttps://tass.com/world/1287621October 1, 20202020 Q4---In February 2021. "The first batch of the Gam-COVID-Vak (Sputnik V) vaccine developed by the Gamaleya National Center has been produced for validation at Belmedpreparaty production facilities, utilizing technology transferred by the Russian company Generium. Upon obtaining the results of the stability study for the first batch of Sputnik V, preparations will begin for mass production. RDIF and its partners are also working on testing the full-cycle technology used for Sputnik V production at facilities in the Republic of Belarus. Production of Sputnik V at Belmedpreparaty sites will meet 100% of vaccine requirements in Belarus in order to protect its citizens against COVID-19." https://rdif.ru/Eng_fullNews/6473/ entire process, active ingredient, others"The three-week laboratory trials of next series of Sputnik V vaccine, which were produced by the Belmedpreparaty enterprise, have been completed at the Gamaleya National Research Center for Epidemiology and Microbiology. The vaccine has passed quality control," the statement says.phase 31.1August 28, 2020-2.7December 21, 2020Belarus2020-10
59
phase 1VLP TherapeuticsFujifilmJapanVLP Therapeutics'RNA-basedhttps://www.fujifilm.com/mm/en/news/hq/5493October 1, 20202020 Q4---entire process, active ingredient, others"Fujifilm will utilize its manufacturing facilities and infrastructure for lipid nanoparticle to handle operations relating to VLP Therapeutics’ COVID-19 vaccine formulations, from process development to manufacturing for clinical trials."pre-clinical2020-10
60
phase 2Arcturus TherapeuticsRecipharmFranceARCT-021, LUNAR-COV19RNA-basedhttps://www.recipharm.com/press/recipharm-signs-agreement-arcturus-therapeutics-support-manufacture-lunar%C2%AE-cov19-arct-021October 6, 20202020 Q4---entire process, active ingredient, others"Arcturus has secured manufacturing slots with Recipharm to support the manufacture of ARCT-021, Arcturus’ COVID-19 vaccine candidate that is in an ongoing phase 1/2 clinical trial."phase 1/22020-10
61
authorizedPfizer/BioNTechRentschler BiopharmaGermanyBNT162b2mRNAhttps://www.rentschler-biopharma.com/news/press-releases-and-announcements/detail/view/joining-forces-against-sars-cov-2/October 7, 20202020 Q4two months1-21-3According to news reports, production started by November 20, 2020: https://www.swr.de/swraktuell/baden-wuerttemberg/friedrichshafen/rentschler-laupheim-beginnt-produktion-fuer-corona-impfstoff-100.htmlentire process, active ingredient, others"key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2"phase 32.4July 27, 2020-1.8December 2, 2020United Kingdom2020-10
62
phase 2VaxartKindred BiosciencesUnited StatesVaxart’sviral vectorhttps://kindredbio.com/frontpage/kindred-biosciences-announces-expansion-of-manufacturing-agreement-with-vaxart-for-covid-19-and-other-vaccine-candidates/October 7, 20202020 Q4---entire process, active ingredient, others"manufacture of Vaxart’s oral vaccine for COVID-19"phase 12020-10
63
authorizedAstraZeneca/OxfordSiam BioscienceThailandAZD1222viral vectorhttps://www.reuters.com/article/us-health-coronavirus-astrazeneca-thaila/thailand-to-make-supply-astrazenecas-covid-19-vaccine-idUSKBN26X1GCOctober 27, 20202020 Q4eight months7-87-9AZ said in April that they were aiming to start production here by June 2021: https://www.astrazeneca.com/country-sites/thailand/press-relaese/thai20210428.htmlentire process, active ingredient, others-phase 2/35.1May 26, 2020-2.1December 30, 2020United Kingdom, Argentina2020-10
64
authorizedGamaleyaUnião QuímicaBrazilSputnik Vviral vectorhttps://rdif.ru/Eng_fullNews/6034/October 30, 20202020 Q4seven months7-87-9União Química made the first batch on May 20, 2021, according to news report: https://www.reuters.com/article/saude-covid-lote-uniaoquimica-idBRKCN2D129S-OBRDNentire process, active ingredient, others-phase 32.1August 28, 2020-1.7December 21, 2020Belarus2020-10
65
authorizedJohnson & JohnsonAspenSouth AfricaAd26.COV2-Sviral vectorhttps://www.aspenpharma.com/2020/11/02/aspen-announces-agreement-with-johnson-johnson-to-manufacture-investigational-covid-19-vaccine-candidate/November 2, 20202020 Q4five months5-64-6On March 12, 2021, Aspen said that it had completed the technology transfer: https://www.bloomberg.com/news/articles/2021-03-12/aspen-pharmacare-to-deliver-j-j-vaccines-in-next-three-monthsentire process, active ingredient, others"for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S"phase 32.8August 10, 2020-3.8February 27, 2021United States2020-11
66
authorizedGamaleyaPharmasyntezRussiaSputnik Vviral vector
https://pharmasyntez.com/en/press-center/news/pharmasyntez-will-produce-the-covid-19-sputnik-v-vaccine/?sphrase_id=15954
November 6, 20202020 Q42.3August 28, 2020-1.5December 21, 2020Belarus2020-11
67
authorizedPfizer/BioNTechCrodaUnited KingdomBNT162b2mRNAhttps://www.croda.com/en-gb/news/2020/11/pfizer-crodaNovember 10, 20202020 Q4one month1-21-3By December 2020 Croda was already suplying Pfizer/BioNTech. https://www.yorkpress.co.uk/news/18925837.covid-vaccine-yorkshire-firm-croda-make-key-parts-jab/ entire process, active ingredient, others"The application of our innovative capabilities is testament to the strong progress we have made to create industry-leading drug delivery systems, focused on developing speciality excipients and adjuvants to improve the effectiveness and stability of complex drug actives and vaccines."phase 33.5July 27, 2020-0.7December 2, 2020United Kingdom2020-11
68
authorizedGamaleyaTibet Rhodiola PharmaChinaSputnik Vviral vectorhttps://www.reuters.com/article/health-coronavirus-vaccine-russia/tibet-rhodiola-pharma-obtains-right-to-develop-russias-sputnik-v-vaccine-in-china-idUSP8N2HR02HNovember 11, 20202020 Q4---entire process, active ingredient, others"develop, manufacture, import or commercialize Russia’s COVID-19 vaccine, Sputnik V, in mainland China, Hong Kong, Macau and Taiwan."phase 32.5August 28, 2020-1.3December 21, 2020Belarus2020-11
69
authorizedGamaleyaGL RaphaSouth KoreaSputnik Vviral vectorhttps://sputnikvaccine.com/newsroom/pressreleases/rdif-and-gl-rapha-agree-to-produce-over-150-million-doses-of-the-sputnik-v-vaccine-in-south-korea/November 13, 20202020 Q4one month1-21-3December 2020entire process, active ingredient, others"produce over 150 million doses per year"phase 32.5August 28, 2020-1.2December 21, 2020Belarus2020-11
70
abandonedCureVacRentschler BiopharmaGermanyCVnCoVRNA-basedhttps://www.curevac.com/en/2021/02/01/curevac-and-rentschler-biopharma-ramp-up-manufacturing-of-covid-19-vaccine-cvncov/November 15, 20202020 Q4three months3-41-3February 1, 2021entire process, active ingredient, others"largescale cGMP (Current Good Manufacturing Practice) production of the formulated mRNA for CVnCoV"phase 2-0.1November 19, 2020abandonedabandoned2020-11
71
authorizedPfizer/BioNTechDelpharmFranceBNT162b2mRNAhttps://pharmacie.ma/index/generate-pdf/article_id/6911November 18, 20202020 Q4six months5-64-6According to several news reports, including in www.fr24news.com, Delpharm would start producing in Saint-Rémy-sur-Avre from April 2021 entire process, active ingredient, others"une partie des doses du vaccin anti-Covid-19 développé par Pfizer et BioNTech"phase 33.7July 27, 2020-0.5December 2, 2020United Kingdom2020-11
72
abandonedCureVacWACKERGermanyCVnCoVRNA-basedhttps://www.curevac.com/en/2020/11/23/curevac-and-wacker-sign-manufacturing-contract-for-curevacs-covid-19-vaccine-candidate-cvncov/November 23, 20202020 Q4eight months7-87-9"first half of 2021"entire process, active ingredient, others"ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV"phase 20.1November 19, 2020abandonedabandoned2020-11
73
authorizedGamaleyaHetero BiopharmaIndiaSputnik Vviral vectorhttps://rdif.ru/Eng_fullNews/6096/November 27, 20202020 Q4six months5-64-6"beginning of 2021"entire process, active ingredient, others"to produce in India over 100 million doses"phase 33.0August 28, 2020-0.8December 21, 2020Belarus2020-11
74
phase 3InovioKaneka EurogentecBelgiumINO-4800DNA-basedhttp://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Expands-Global-Manufacturing-Consortium-For-Its-COVID-19-Vaccine-Candidate-INO-4800-With-Addition-of-Kaneka-Eurogentec-S.A/default.aspxDecember 3, 20202020 Q4---entire process, active ingredient, others"manufacture INOVIO's COVID-19 vaccine candidate INO-4800 at their industry-leading GMP plasmid production scales"phase 20.3November 24, 20202020-12
75
authorizedGamaleyaKaraganda PharmaceuticalKazakhstanSputnik Vviral vectorhttps://www.themoscowtimes.com/2021/02/16/kazakhstan-to-roll-out-first-locally-produced-sputnik-vaccine-a72971December 4, 20202020 Q4---entire process, active ingredient, others"local production of Sputnik V"phase 33.2August 28, 2020-0.6December 21, 2020Belarus2020-12
76
authorizedAstraZeneca/OxfordHALIXNetherlandsAZD1222viral vectorhttps://www.halix.nl/2020/12/08/halix-signs-agreement-astrazeneca-commercial-manufacture-covid-19-vaccine/December 8, 20202020 Q4four months3-44-6According to news reports, Halix was already producting by late March 2021: https://fortune.com/2021/03/26/astrazeneca-plant-halix-covid-vaccines-ema/ Halix appears to have been collaborating with Oxford prior to this. entire process, active ingredient, others"commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands"phase 2/36.4May 26, 2020-0.7December 30, 2020United Kingdom, Argentina2020-12
77
abandonedCureVacFarevaFranceCVnCoVRNA-basedhttps://www.curevac.com/2020/12/09/curevac-and-fareva-sign-agreement-for-fill-finish-manufacturing-of-curevacs-covid-19-vaccine-candidate-cvncov/December 9, 20202020 Q4six months5-64-6May 2021, according to France Industry Minister Agnès Pannier-Runacherfill-and-finishfill-and-finishphase 20.7November 19, 2020abandonedabandoned2020-12
78
authorizedJohnson & JohnsonReig JofreSpainAd26.COV2-Sviral vectorhttps://www.reigjofre.com/en/noticias/item/reig-jofre-announces-technology-transfer-of-the-large-scale-manufacturing-in-spain-for-a-covid-19-vaccine-candidate/December 15, 20202020 Q4six months5-64-6In late April 2021 Reig Jofre said that the production delivery in expected to start in June 2021: https://cincodias.elpais.com/cincodias/2021/04/29/companias/1619693087_591444.htmlentire process, active ingredient, others"formulation, filling, and packaging of the vaccine candidate"phase 34.2August 10, 2020-2.4February 27, 2021United States2020-12
79
authorizedBharat BiotechOcugen IncUnited StatesCovaxininactivated virushttps://ir.ocugen.com/news-releases/news-release-details/ocugen-and-bharat-biotech-co-develop-covaxintm-whole-virionDecember 22, 20202020 Q4---entire process, active ingredient, others"Ocugen will have US rights to the vaccine candidate and, in collaboration with Bharat Biotech, will be responsible for clinical development, registration, and commercialization for the US market. The companies have begun collaborating and will finalize details of the definitive agreement in the next few weeks. This collaboration leverages Ocugen’s vaccine expertise, and its R&D and regulatory capabilities in the US."phase 31.0November 23, 2020-0.4January 3, 2021India2020-12
80
authorizedAstraZeneca/OxfordJCR PharmaceuticalJapanAZD1222viral vectorhttps://pj.jiho.jp/article/243572December 30, 20202020 Q4three months3-41-3In a March 4, 2021 statement the JCR said that they were already manufacturing the bulk substance. "JCR has been manufacturing the bulk substance of the vaccine at JCR’s existing plant" https://ssl4.eir-parts.net/doc/4552/tdnet/1941163/00.pdf entire process, active ingredient, others"JCR Pharmaceuticals has signed a pact with AstraZeneca for the domestic production of vaccine solutions for AZD1222, the UK giant’s COVID-19 shot being codeveloped with Oxford University, the Japanese company said on December 30." autorized7.2May 26, 20200.0December 30, 2020United Kingdom, Argentina2020-12
81
authorizedModernaRecipharm ABSwedenmRNA-1273mRNAhttps://www.recipharm.com/press/recipharm-and-moderna-finalize-agreement-aseptic-drug-product-manufacturing-and-fill-finishDecember 30, 20202020 Q4three months3-41-3"supply will commence in early 2021"entire process, active ingredient, others"aseptic drug product manufacturing and fill-finish"autorized5.1July 27, 20200.4December 18, 2020United States2020-12
82
phase 3InovioAdvaccine BiopharmaceuticalsChinaINO-4800DNA-basedhttps://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-and-Advaccine-Announce-Exclusive-Partnership-To-Commercialize-COVID-19-DNA-Vaccine-Candidate-INO-4800-in-Greater-China/default.aspxJanuary 4, 20212021 Q1---entire process, active ingredient, others"Advaccine will have the exclusive right to develop, manufacture and commercialize INO-4800 within Greater China, inclusive of Mainland China, Hong Kong, Macao, and Taiwan."phase 21.3November 24, 20202021-1
83
abandonedCureVacBayerGermanyCVnCoVRNA-basedhttps://media.bayer.com/baynews/baynews.nsf/id/CureVac-and-Bayer-join-forces-on-COVID-19-vaccine-candidate-CVnCoVJanuary 7, 20212021 Q1---entire process, active ingredient, others"Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV"phase 31.6November 19, 2020abandonedabandoned2021-1
84
authorizedFinlay InstitutePasteur InstituteIranSoberanaprotein-basedhttps://www.finlay.edu.cu/blog/joint-statement-of-finlay-vaccine-institute-and-pasteur-institute-of-iran/January 8, 20212021 Q1six months5-64-6Iran started producing in July 2021, six months after the January 2021 agreement: https://www.reuters.com/business/healthcare-pharmaceuticals/cuba-says-iran-start-producing-one-its-covid-19-vaccines-2021-07-29/ -1.9March 8, 2021-7.4August 20, 2021Cuba2021-1
85
authorizedNovavaxBaxterGermanyNVX-CoV2373protein-basedhttps://www.baxter.com/baxter-newsroom/baxter-biopharma-solutions-announces-sterile-manufacturing-agreement-novavax-covidJanuary 11, 20212021 Q1----entire process, active ingredient, others"sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M™ adjuvant"phase 33.0October 12, 2020-11.3December 20, 2021EMA2021-1
86
authorizedSinovacPharmaniaga BerhadMalaysiaCoronaVacinactivated virushttps://www.thestar.com.my/business/business-news/2021/01/13/pharmaniaga-to-produce-sinovac-covid-19-vaccinesJanuary 11, 20212021 Q1three months3-41-3"Phamaniaga Bhd has the capacity to manufacture two million doses of Covid-19 vaccine developed by China’s Sinovac Life Sciences Co Ltd per month beginning March this year." https://www.thestar.com.my/business/business-news/2021/01/13/pharmaniaga-to-produce-sinovac-covid-19-vaccines fill-and-finishfill-and-finishautorized6.3July 2, 20200.0January 11, 2021Indonesia2021-1
87
authorizedSinovacLekhimUkraineCoronaVacinactivated virushttps://www.reuters.com/article/us-health-coronavirus-ukraine-vaccine/ukraine-pharma-group-to-supply-5-million-doses-of-sinovac-covid-19-vaccine-in-first-half-idUSKBN29H1QZJanuary 12, 20212021 Q1three months3-41-3"Ukrainian company Lekhim will deliver the first batch of the Chinese-made Sinovac COVID-19 vaccines to Ukraine by March 15, the company said on Thursday." https://www.reuters.com/article/us-health-coronavirus-ukraine-vaccine/ukraine-firm-lekhim-will-deliver-first-batch-of-sinovac-vaccines-by-march-15-idUSKBN2AW1FB entire process, active ingredient, others-autorized6.4July 2, 20200.0January 11, 2021Indonesia2021-1
88
authorizedPfizer/BioNTechBaxterGermanyBNT162b2mRNAhttps://www.reuters.com/article/health-coronavirus-vaccines-baxter-intl/update-1-baxter-to-start-production-in-germany-of-biontech-pfizer-vaccine-by-early-march-idUSL8N2JO32DJanuary 13, 20212021 Q1two months1-21-3"The U.S. healthcare group plans to start production at its facility in Halle, North Rhine-Westphalia, in late February or early March, said Juergen Fleischer, personnel chief at Baxter Germany." https://www.reuters.com/article/health-coronavirus-vaccines-baxter-intl/update-1-baxter-to-start-production-in-germany-of-biontech-pfizer-vaccine-by-early-march-idUSL8N2JO32D fill-and-finishfill and finishautorized5.6July 27, 20201.4December 2, 2020United Kingdom2021-1
89
authorizedAstraZeneca/OxfordInsud PharmaSpainAZD1222viral vectorhttps://www.insudpharma.com/spanish-group-insud-pharma-signs-agreement-astrazeneca-manufacture-covid-19-vaccine-candidateJanuary 20, 20212021 Q1one month1-21-3"AstraZeneca has partnered with the Spanish pharmaceutical group Insud Pharma to participate in the manufacturing of the vaccine vials developed in collaboration with Oxford University to fight against the COVID-19 pandemic. Universal Farma's facilities in Azuqueca de Henares (Guadalajara) will start to fill and package the AZD1222 vials in February 2021." https://www.investinspain.org/en/news/2021/astrazeneca-insudpharma-produce-vaccine fill-and-finish"The Spanish pharmaceutical group Insud Pharma will provide vial filling and packaging of AZD1222, the adenovirus vector COVID-19 vaccine candidate developed by the University of Oxford and licensed by AstraZeneca. Manufacturing will take place in the plant operated by the group's industrial unit, Chemo. AZD1222 is currently in clinical trials and approved for emergency supply in UK and other countries."autorized7.9May 26, 20200.7December 30, 2020United Kingdom, Argentina2021-1
90
authorizedGamaleyaVisCoranTurkeySputnik Vviral vectorhttps://www.viscoran.com/-Sputnik-Vnin-Turkiyede-uretimi-icin-imzalar-atildi-d3January 21, 20212021 Q1six months5-64-6In April 2021 the RDIF said that VisCoran was going to start producing "in the upcoming months." "To date Viscoran İlaç has carried out necessary studies for localization of the product and aims to launch the production in the country in the upcoming months at several facilities." https://sputnikvaccine.com/newsroom/pressreleases/rdif-and-viscoran-ilac-agree-to-produce-the-sputnik-v-vaccine-in-turkey/ entire process, active ingredient, others-autorized4.8August 28, 20201.0December 21, 2020Belarus2021-1
91
authorizedGamaleyaDuopharma BiotechMalaysiaSputnik Vviral vectorhttps://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=111133&name=EA_GA_ATTACHMENTSJanuary 26, 20212021 Q1---fill-and-finish"Duopharma Biotech has invested in vaccine fill & finish and cold chain facilities to align with Malaysia’s aim to advance towards developing in-country vaccines inthe long term"autorized5.0August 28, 20201.2December 21, 2020Belarus2021-1
92
authorizedPfizer/BioNTechSanofiFranceBNT162b2mRNAhttps://www.sanofi.com/en/media-room/press-releases/2021/2021-01-27-07-30-00January 27, 20212021 Q1six months5-64-6"summer of 2021"fill-and-finish"Sanofi will perform late-stage manufacturing to supply over 125 million doses of COVID-19 vaccine for the European Union"autorized6.0July 27, 20201.8December 2, 2020United Kingdom2021-1
93
authorizedPfizer/BioNTechNovartisSwitzerlandBNT162b2mRNAhttps://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-provide-manufacturing-capacity-pfizer-biontech-covid-19-vaccineJanuary 29, 20212021 Q1six months5-64-6"Subject to reaching a final agreement, Novartis plans to commence production in the second quarter of 2021 at its state-of-the art aseptic manufacturing plant in Stein."fill-and-finish"Novartis plans to take bulk mRNA active ingredient from BioNTech and fill this into vials under aseptic conditions for shipment back to BioNTech for their distribution to healthcare system customers around the world."autorized6.1July 27, 20201.9December 2, 2020United Kingdom2021-1
94
authorizedPfizer/BioNTechAllergopharmaGermanyBNT162b2mRNAhttps://allergopharmanexter.pl/application/files/1516/1425/3193/Press-Release-COVID-19.pdfFebruary 1, 20212021 Q1three months3-41-3From April 30, 2021. "After a very short preparation period, Allergopharma officially starts production of the BioNTech vaccine Comirnaty ® in Reinbek today." https://www.allergopharma.de/unternehmen/aktuelle-nachrichten-covid-vaccine/ entire process, active ingredient, others"The company Aller-gopharma will soon be producing the COVID-19 vaccine of the Mainz company BioNTech in new, ultra-modern production facilities in Reinbek near Hamburg (see photo)."autorized6.2July 27, 20202.0December 2, 2020United Kingdom2021-2
95
authorizedAstraZeneca/OxfordKM BiologicsJapanAZD1222viral vectorhttps://pj.jiho.jp/article/244060February 1, 20212021 Q1two months1-21-3KM Biologics started production in March 2021. https://pj.jiho.jp/article/244060fill-and-finish"Daiichi Sankyo Biotech and KM Biologics will undertake production, such as filling vials and packaging, while Daiichi Sankyo and Meiji Seika Pharma will support shipping."autorized8.2May 26, 20201.1December 30, 2020United Kingdom, Argentina2021-2
96
authorizedCanSino BiologicsDrugmexMexicoAd5-nCoVviral vectorhttps://www.reuters.com/article/us-health-coronavirus-mexico-vaccine/chinas-cansino-says-first-vaccines-packaged-in-mexico-will-be-ready-in-march-idUSKCN2AS0P0February 1, 20212021 Q1two months1-21-3The first batch was out by March 2021: https://www.gob.mx/sre/prensa/the-first-covid-19-vaccines-packaged-in-mexico-leave-the-drugmex-plantfill-and-finishfill-and-finishphase 35.2August 26, 2020-0.3February 10, 2021Mexico2021-2
97
authorizedNovavaxBiologics Manufacturing Centre, CanadaCanadaNVX-CoV2373protein-basedhttps://nrc.canada.ca/en/research-development/nrc-facilities/biologics-manufacturing-centreFebruary 2, 20212021 Q1six months5-64-6"end of July 2021"entire process, active ingredient, others"Government of Canada signed a memorandum of understanding with Novavax in February 2021 to pursue options to produce its COVID-19 vaccine"phase 33.7October 12, 2020-10.5December 20, 2021EMA2021-2
98
abandonedCureVacGSKUnited KingdomCVnCoVRNA-basedhttps://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/February 3, 20212021 Q1---entire process, active ingredient, others"GSK will also support the manufacture of up to 100 million doses of CureVac’s first generation COVID-19 vaccine candidate CVnCoV in 2021"phase 32.5November 19, 2020abandonedabandoned2021-2
99
authorizedAstraZeneca/OxfordDaiichi SankyoJapanAZD1222viral vectorhttps://www.daiichisankyo.com/files/news/pressrelease/pdf/202102/20210205_E.pdfFebruary 5, 20212021 Q1two months1-21-3Daiichi Sankyo announced in March 12, 2021, that they started manufacturing. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202103/20210312_E1.pdf fill-and-finish"Daiichi Sankyo will use undiluted solutions provided by AstraZeneca to manufacture COVID-19 vaccines in the country, including vial filling and packaging, in accordance with the outsourcing agreement."autorized8.4May 26, 20201.2December 30, 2020United Kingdom, Argentina2021-2
100
authorizedPfizer/BioNTechMerck United StatesBNT162b2mRNAhttps://www.emdgroup.com/en/news/biontech-strategic-partnership-04-02-2021.htmlFebruary 5, 20212021 Q1---entire process, active ingredient, otherslipid productionautorized6.3July 27, 20202.1December 2, 2020United Kingdom2021-2